EPIX ESSA Pharma Quarterly EPS earnings growth

ESSA Pharma - graphic logo of issuer EPIX

ESSA Pharma Inc. (EPIX) develops targeted oncology drugs, where success depends on FDA approval and patents. The quarterly earnings per share growth rate reflects the business revaluation dynamics, and this figure equals 43.90. Management is focusing on innovative receptor blocking for the therapy of resistant forms of cancer. The Aniten platform provides a stable moat, enabling the suppression of dangerous tumors in collaboration with industry leaders.

essapharma.com (EPIX) Year-over-year earnings per share growth for the last 12 months: for the period 07/04/2022 - 10/25/2025

Summary analytical data breakdowns for ESSA Pharma Inc. (EPIX)

- market value and analyst target forecast:
Price Chart essapharma.com|EPIX - Consensus Target
- market capitalization data:
Market Capitalization ESSA Pharma Inc|EPIX - Total Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share ESSA Pharma|EPIX - Accounting Capitalization|Market Capitalization to Book Value Ratio essapharma.com|EPIX - Company Assets
- company liabilities and liquidity data:
Debt to Equity ESSA Pharma Inc.|EPIX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity essapharma.com|EPIX - Company Total Debt Obligations|Debts to Book Capitalization ESSA Pharma Inc|EPIX - Company Long-Term Debts|Company Current Liabilities ESSA Pharma|Quick Liquidity essapharma.com
- earnings and market multiples details:
EPIX - Profit After Tax|Projected Future Earnings ESSA Pharma Inc.|EPIX - Company Value to Net Income|Forward P/E Multiple essapharma.com|EPIX - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ESSA Pharma Inc|EPIX - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months ESSA Pharma|EPIX - Net earnings per share for the last 12 months|Quarterly EPS earnings growth essapharma.com|EPIX - Earnings growth in current year|Expected earnings per share growth for next year ESSA Pharma Inc.
Analysis of all company metrics:ESSA Pharma, Inc. - EPIX
Manufactured product of essapharma.com

ESSA Pharma Inc. is developing innovative targeted prostate cancer therapies, where brand capitalization depends on the success of clinical developments. By analyzing the quarterly EPS growth vector on GURU.Markets, an investor can track net profit per share compared to previous periods, allowing for an assessment of technology commercialization efficiency and the sustainability of the company's fundamental trend.

Competitor analysis

Merus (MRUS) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months Immutep Ltd|ANIX (Anixa Biosciences Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Atossa Pharma ATOS|Year-over-year earnings per share growth for the last twelve months Context Therapeutics (CNTX)|mersana.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth BCTX (BriaCell)|QT Imaging Holdings (QTI) - Earnings per share growth in annualized terms for the last twelve months